Credit rating agency, India Ratings & Research has assigned Cipla a long-term issuer rating of ‘AAA’ with a stable outlook. The rating agency has also assigned the company’s Rs 2000 crore proposed non-convertible debenture (NCD) issuance an expected rating of ‘AAA(exp)’. Further, the rating agency has affirmed Cipla’s Rs 1000 crore commercial paper/short term debt programme at ‘A1+’.
The company has received the said rating on the back of its strong business profile driven by its geographical and product diversification. The ratings also reflect the company’s conservative strategy of building a distribution network in export markets through the use of partnerships and JVs. This has kept its balance sheet asset light with low reliance on debt.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: